Immunovant Inc
IMVT · NASDAQ
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Market Data
Price
$27.15
+0.20 (+0.72%)
Market Cap$5.49B
P/E Ratio—
EPS$—
52W High$30.09
52W Low$13.36
Beta0.72
Data from Finnhub · Updated May 1, 2026